New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
06:31 EDTOREXOrexigen receives three month extension of FDA NB32 review
Orexigen announced that the FDA has extended its review of the resubmitted New Drug Application for NB32, the company's investigational medication being evaluated for weight loss. The new Prescription Drug User Fee Act action date has been set for September 11. The FDA has indicated that the review extension is needed to reach agreement on the post-marketing obligation related to the previously agreed upon evaluation of cardiovascular outcomes for NB32. The NDA resubmission package includes interim safety and CV outcomes data from the ongoing 8,900 patient Light Study. Discussions around the package insert and other post-marketing obligations are ongoing.
News For OREX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
10:12 EDTOREXOptions with decreasing implied volatility
Subscribe for More Information
May 13, 2015
08:08 EDTOREXOrexigen price target lowered to $8 from $11 at Leerink
Subscribe for More Information
May 12, 2015
19:33 EDTOREXOrexigen provides update on Contrave collaboration with Takeda
Subscribe for More Information
19:32 EDTOREXOrexigen provides statement on termination of Light Study
Subscribe for More Information
17:54 EDTOREXOn The Fly: After Hours Movers
Subscribe for More Information
17:52 EDTOREXTakeda requesting Orexigen to pay cost of second heart trial, Bloomberg says
Subscribe for More Information
15:17 EDTOREXOrexigen weakness a buying opportunity, says Piper Jaffray
Subscribe for More Information
08:38 EDTOREXTakeda and Orexigen accept recommendation of the ESC
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use